First Trust Advisors
AGIO icon

First Trust Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

First Trust Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-78,656
Closed -$2.14M – 2606
2025
Q4 		$2.14M Buy
78,656
+4,227
+6% +$148K ﹤0.01% 1853
2025
Q3 		$2.99M Buy
74,429
+38,002
+104% +$1.43M ﹤0.01% 1642
2025
Q2 		$1.21M Sell
36,427
-903
-2% -$27.4K ﹤0.01% 2017
2025
Q1 		$1.09M Sell
37,330
-59,929
-62% -$1.99M ﹤0.01% 2016
2024
Q4 		$3.2M Sell
97,259
-13,664
-12% -$642K ﹤0.01% 1614
2024
Q3 		$4.93M Sell
110,923
-19,488
-15% -$885K ﹤0.01% 1354
2024
Q2 		$5.62M Buy
+130,411
New +$4.71M 0.01% 1214
2024
Q1 		– Sell
-1,818,643
Closed -$40.5M – 2334
2023
Q4 		$40.5M Buy
1,818,643
+43,476
+2% +$974K 0.04% 485
2023
Q3 		$43.9M Sell
1,775,167
-385,409
-18% -$10.2M 0.05% 454
2023
Q2 		$61.2M Buy
2,160,576
+322,959
+18% +$8.04M 0.07% 397
2023
Q1 		$42.2M Buy
1,837,617
+206,791
+13% +$5.49M 0.05% 482
2022
Q4 		$45.8M Sell
1,630,826
-355,339
-18% -$10M 0.05% 468
2022
Q3 		$56.2M Buy
1,986,165
+256,511
+15% +$6.88M 0.07% 416
2022
Q2 		$38.3M Buy
1,729,654
+116,225
+7% +$2.63M 0.05% 509
2022
Q1 		$47M Buy
1,613,429
+344,959
+27% +$10.5M 0.05% 518
2021
Q4 		$41.7M Buy
1,268,470
+167,687
+15% +$6.75M 0.04% 549
2021
Q3 		$50.8M Sell
1,100,783
-395,313
-26% -$19.1M 0.05% 457
2021
Q2 		$82.5M Sell
1,496,096
-63,405
-4% -$3.55M 0.09% 298
2021
Q1 		$80.5M Sell
1,559,501
-262,880
-14% -$13M 0.1% 271
2020
Q4 		$79M Buy
1,822,381
+16,839
+0.9% +$666K 0.1% 249
2020
Q3 		$63.2M Buy
1,805,542
+215,151
+14% +$9.43M 0.1% 262
2020
Q2 		$85.1M Buy
1,590,391
+337,397
+27% +$15.6M 0.15% 166
2020
Q1 		$44.5M Sell
1,252,994
-280,755
-18% -$13M 0.1% 313
2019
Q4 		$73.2M Buy
1,533,749
+238,728
+18% +$9.02M 0.13% 210
2019
Q3 		$42M Sell
1,295,021
-495,105
-28% -$20.5M 0.08% 371
2019
Q2 		$89.3M Buy
1,790,126
+15,968
+0.9% +$853K 0.17% 146
2019
Q1 		$120M Buy
1,774,158
+423,931
+31% +$24.7M 0.24% 86
2018
Q4 		$62.3M Buy
1,350,227
+188,217
+16% +$11.6M 0.15% 162
2018
Q3 		$89.6M Buy
1,162,010
+430,216
+59% +$34.6M 0.17% 132
2018
Q2 		$61.6M Buy
731,794
+56,038
+8% +$4.89M 0.13% 162
2018
Q1 		$55.3M Sell
675,756
-137,891
-17% -$10.7M 0.13% 163
2017
Q4 		$46.5M Buy
813,647
+169,331
+26% +$10.7M 0.11% 212
2017
Q3 		$43M Sell
644,316
-329,554
-34% -$19.8M 0.11% 204
2017
Q2 		$50.1M Buy
973,870
+334,291
+52% +$17.1M 0.13% 168
2017
Q1 		$37.4M Buy
639,579
+96,712
+18% +$4.64M 0.1% 220
2016
Q4 		$22.7M Sell
542,867
-107,465
-17% -$5.64M 0.07% 401
2016
Q3 		$34.4M Buy
650,332
+59,261
+10% +$2.58M 0.1% 227
2016
Q2 		$24.8M Sell
591,071
-11,746
-2% -$580K 0.08% 331
2016
Q1 		$24.5M Sell
602,817
-861,129
-59% -$36.8M 0.08% 322
2015
Q4 		$95M Sell
1,463,946
-159,484
-10% -$10.5M 0.25% 84
2015
Q3 		$115M Buy
1,623,430
+544,144
+50% +$53.2M 0.33% 52
2015
Q2 		$120M Buy
+1,079,286
New +$116M 0.31% 59

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

First Trust Advisors's AGIO Position: Q1 2026 in Review

First Trust Advisors sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 78,656 shares — an estimated $2.14M sold.

First Trust Advisors first reported a position in AGIO in Q2 2015 and held it in 42 quarters. The position peaked at $120M in Q2 2015. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • First Trust Advisors reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • First Trust Advisors sold 78,656 Agios Pharmaceuticals shares in Q1 2026, an estimated $2.14M.
  • First Trust Advisors first reported a position in Agios Pharmaceuticals in Q2 2015 and held it in 42 quarters.
  • First Trust Advisors's Agios Pharmaceuticals position peaked at $120M in Q2 2015.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.